{"transactions":[{"id":1267390,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-14T16:08:54.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":850000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date."}],"balance_after":850000,"source":{"system":"sec-edgar","filing":"0001628280-25-005702","document":"wk-form4_1739567322.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828025005702/wk-form4_1739567322.xml","form_type":"4"}},{"id":1294514,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-27T18:15:43.000Z","date":"2025-01-24","kind":"sale","planned":false,"acquired":false,"shares":74773,"price":0.454,"value":33946.942,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.447 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-25-002708","document":"wk-form4_1738019736.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828025002708/wk-form4_1738019736.xml","form_type":"4"}},{"id":1294513,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-27T18:15:43.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":74773,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome."}],"balance_after":74773,"source":{"system":"sec-edgar","filing":"0001628280-25-002708","document":"wk-form4_1738019736.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828025002708/wk-form4_1738019736.xml","form_type":"4"}},{"id":1389365,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-10-08T16:44:42.000Z","date":"2024-10-07","kind":"sale","planned":false,"acquired":false,"shares":230645,"price":0.5502,"value":126900.879,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5144 to $0.6036, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-24-042545","document":"wk-form4_1728420276.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828024042545/wk-form4_1728420276.xml","form_type":"4"}},{"id":1389364,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-10-08T16:44:42.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":230645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of the performance condition."}],"balance_after":230645,"source":{"system":"sec-edgar","filing":"0001628280-24-042545","document":"wk-form4_1728420276.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828024042545/wk-form4_1728420276.xml","form_type":"4"}},{"id":1584288,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-11T17:19:52.000Z","date":"2024-03-11","kind":"sale","planned":false,"acquired":false,"shares":52500,"price":0.8828,"value":46347.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.8649 to $0.9147, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-24-010279","document":"wk-form4_1710191979.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828024010279/wk-form4_1710191979.xml","form_type":"4"}},{"id":1638339,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Appreciation Right","published_at":"2024-02-16T17:10:00.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":523414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date."}],"balance_after":523414,"derivative":{"exercise_price":0.921,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":523414},"source":{"system":"sec-edgar","filing":"0001628280-24-005384","document":"wk-form4_1708121388.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828024005384/wk-form4_1708121388.xml","form_type":"4"}},{"id":1649385,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-12T17:03:58.000Z","date":"2024-02-12","kind":"sale","planned":false,"acquired":false,"shares":27721,"price":1.0091,"value":27973.2611,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.97 to $1.07, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":52500,"source":{"system":"sec-edgar","filing":"0001628280-24-004263","document":"wk-form4_1707775417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828024004263/wk-form4_1707775417.xml","form_type":"4"}},{"id":1749885,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-03T16:42:15.000Z","date":"2023-11-01","kind":"sale","planned":true,"acquired":false,"shares":230645,"price":0.73,"value":168370.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6835 to $0.7911, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":80221,"source":{"system":"sec-edgar","filing":"0001628280-23-036758","document":"wk-form4_1699044122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828023036758/wk-form4_1699044122.xml","form_type":"4"}},{"id":1751419,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-02T17:04:31.000Z","date":"2023-10-31","kind":"grant","planned":false,"acquired":true,"shares":230645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor."}],"balance_after":310866,"source":{"system":"sec-edgar","filing":"0001628280-23-036471","document":"wk-form4_1698959058.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828023036471/wk-form4_1698959058.xml","form_type":"4"}},{"id":1836421,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-07-05T16:04:44.000Z","date":"2023-06-30","kind":"sale","planned":false,"acquired":false,"shares":2641,"price":1.89,"value":4991.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.84 to $1.95 inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents restricted stock units."}],"balance_after":80221,"source":{"system":"sec-edgar","filing":"0001628280-23-024228","document":"wk-form4_1688587453.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828023024228/wk-form4_1688587453.xml","form_type":"4"}},{"id":1844256,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-26T16:13:24.000Z","date":"2023-06-23","kind":"sale","planned":false,"acquired":false,"shares":5417,"price":1.93,"value":10454.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.90 to $1.96 inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents restricted stock units."}],"balance_after":82862,"source":{"system":"sec-edgar","filing":"0001628280-23-023443","document":"wk-form4_1687810394.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828023023443/wk-form4_1687810394.xml","form_type":"4"}},{"id":1852426,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-16T16:17:14.000Z","date":"2023-06-15","kind":"sale","planned":false,"acquired":false,"shares":5417,"price":2.22,"value":12025.74,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $2.14 to $2.39, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents restricted stock units."}],"balance_after":88279,"source":{"system":"sec-edgar","filing":"0001628280-23-022473","document":"wk-form4_1686946623.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828023022473/wk-form4_1686946623.xml","form_type":"4"}},{"id":1956881,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-13T16:50:56.000Z","date":"2023-03-10","kind":"sale","acquired":false,"shares":52500,"price":0.84,"value":44100.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.82 to $0.90, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents restricted stock units."}],"balance_after":93696,"source":{"system":"sec-edgar","filing":"0001628280-23-007722","document":"wf-form4_167874064200077.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828023007722/wf-form4_167874064200077.xml","form_type":"4"}},{"id":2013678,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-15T17:12:45.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":27721,"price":0.93,"value":25780.53,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.91 to $0.98, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents restricted stock units."}],"balance_after":146196,"source":{"system":"sec-edgar","filing":"0001628280-23-003757","document":"wf-form4_167649914450211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828023003757/wf-form4_167649914450211.xml","form_type":"4"}},{"id":2121238,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Appreciation Right","published_at":"2022-11-09T16:22:51.000Z","date":"2022-11-07","kind":"grant","acquired":true,"shares":1350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of November 7, 2022, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date."}],"balance_after":1350000,"derivative":{"exercise_price":1.8,"expiration_date":"2032-11-07","underlying":"Common Stock","underlying_shares":1350000},"source":{"system":"sec-edgar","filing":"0001628280-22-029261","document":"wf-form4_166802894353588.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828022029261/wf-form4_166802894353588.xml","form_type":"4"}},{"id":2178326,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-19T13:04:21.000Z","date":"2022-08-17","kind":"sale","acquired":false,"shares":10834,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.150 to $1.215, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents unvested restricted stock units."}],"balance_after":173917,"source":{"system":"sec-edgar","filing":"0001628280-22-023323","document":"wf-form4_166092864529306.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828022023323/wf-form4_166092864529306.xml","form_type":"4"}},{"id":2217381,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-07-01T17:01:02.000Z","date":"2022-06-30","kind":"sale","acquired":false,"shares":2641,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.88 to $0.92, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents unvested restricted stock units."}],"balance_after":184751,"source":{"system":"sec-edgar","filing":"0001628280-22-018400","document":"wf-form4_165670924581616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828022018400/wf-form4_165670924581616.xml","form_type":"4"}},{"id":2221240,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-06-27T16:14:48.000Z","date":"2022-06-24","kind":"sale","acquired":false,"shares":5416,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.06 to $1.11, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents unvested restricted stock units."}],"balance_after":187392,"source":{"system":"sec-edgar","filing":"0001628280-22-018047","document":"wf-form4_165636087288621.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828022018047/wf-form4_165636087288621.xml","form_type":"4"}},{"id":2228033,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-06-17T16:22:51.000Z","date":"2022-06-16","kind":"sale","acquired":false,"shares":5416,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.03 to $1.13, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents unvested restricted stock units."}],"balance_after":192808,"source":{"system":"sec-edgar","filing":"0001628280-22-017438","document":"wf-form4_165549734296466.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828022017438/wf-form4_165549734296466.xml","form_type":"4"}},{"id":2365596,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-03-01T16:09:28.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents unvested restricted stock units."}],"balance_after":198224,"source":{"system":"sec-edgar","filing":"0001628280-22-004497","document":"wf-form4_164616893696670.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828022004497/wf-form4_164616893696670.xml","form_type":"4"}},{"id":2398226,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-14T16:23:15.000Z","date":"2022-02-11","kind":"sale","acquired":false,"shares":27721,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.52 to $1.74, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents unvested restricted stock units."}],"balance_after":93224,"source":{"system":"sec-edgar","filing":"0001628280-22-002511","document":"wf-form4_164487375572326.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828022002511/wf-form4_164487375572326.xml","form_type":"4"}},{"id":2596245,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-19T16:26:43.000Z","date":"2021-08-17","kind":"sale","acquired":false,"shares":10832,"price":5.1,"value":55243.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $4.98 to $5.35, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents unvested restricted stock units."}],"balance_after":120945,"source":{"system":"sec-edgar","filing":"0001628280-21-017333","document":"wf-form4_162940478600346.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828021017333/wf-form4_162940478600346.xml","form_type":"4"}},{"id":2647805,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-07-01T08:18:29.000Z","date":"2021-06-30","kind":"sale","acquired":false,"shares":2641,"price":6.64,"value":17536.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $6.50 to $6.78, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents unvested restricted stock units."}],"balance_after":131777,"source":{"system":"sec-edgar","filing":"0001628280-21-013299","document":"wf-form4_162514188426351.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828021013299/wf-form4_162514188426351.xml","form_type":"4"}},{"id":2654839,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-25T16:03:59.000Z","date":"2021-06-24","kind":"sale","acquired":false,"shares":5417,"price":7.01,"value":37973.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $6.89 to $7.28, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Represents unvested restricted stock units."}],"balance_after":134418,"source":{"system":"sec-edgar","filing":"0001628280-21-012933","document":"wf-form4_162465141949892.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828021012933/wf-form4_162465141949892.xml","form_type":"4"}},{"id":2654838,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-25T16:03:59.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units issued to the Reporting Person.  Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date.  One third of the shares underlying the restricted stock unit award vested on June 23, 2021.  One third of the shares will vest on June 23, 2022, and one third of the shares will vest on June 23, 2023, subject to the Reporting Person providing continuous service to the Issuer on such dates.  Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs."}],"balance_after":139835,"source":{"system":"sec-edgar","filing":"0001628280-21-012933","document":"wf-form4_162465141949892.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828021012933/wf-form4_162465141949892.xml","form_type":"4"}},{"id":2663977,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-17T17:13:29.000Z","date":"2021-06-15","kind":"sale","acquired":false,"shares":5417,"price":7.84,"value":42469.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.74 to $8.20, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Represents unvested restricted stock units."}],"balance_after":123585,"source":{"system":"sec-edgar","filing":"0001628280-21-012477","document":"wf-form4_162396433610629.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828021012477/wf-form4_162396433610629.xml","form_type":"4"}},{"id":2663976,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-17T17:13:29.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units issued to the Reporting Person.  Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date.  One third of the shares underlying the restricted stock unit award vested on June 15, 2021.  One third of the shares will vest on June 15, 2022, and one third of the shares will vest on June 15, 2023, subject to the Reporting Person providing continuous service to the Issuer on such dates.  Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs."}],"balance_after":129002,"source":{"system":"sec-edgar","filing":"0001628280-21-012477","document":"wf-form4_162396433610629.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828021012477/wf-form4_162396433610629.xml","form_type":"4"}},{"id":2772025,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-25T17:09:37.000Z","date":"2021-03-24","kind":"grant","acquired":true,"shares":83163,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 11, 2022, February 11, 2023 and February 11, 2024 subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents unvested restricted stock units."}],"balance_after":112752,"source":{"system":"sec-edgar","filing":"0001628280-21-005667","document":"wf-form4_161670655632254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828021005667/wf-form4_161670655632254.xml","form_type":"4"}},{"id":3025053,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-09-22T16:11:28.000Z","date":"2020-09-21","kind":"sale","acquired":false,"shares":10834,"price":7.08,"value":76704.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.01 to $7.18, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents unvested restricted stock units."}],"balance_after":29589,"source":{"system":"sec-edgar","filing":"0001628280-20-013832","document":"wf-form4_160080547296478.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828020013832/wf-form4_160080547296478.xml","form_type":"4"}},{"id":3054495,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-08-18T20:16:10.000Z","date":"2020-08-17","kind":"grant","acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted stock units issued to the Reporting Person.  Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date.  One third of the shares underlying the restricted stock unit award vested on August 17, 2020.  One third of the shares will vest on August 17, 2021, and one third of the shares will vest on August 17, 2022, subject to the Reporting Person providing continuous service to the Issuer on such dates.  Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Of the shares of common stock reported, 29,589 shares represent unvested restricted stock units."}],"balance_after":40423,"source":{"system":"sec-edgar","filing":"0001628280-20-012846","document":"wf-form4_159779615491282.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828020012846/wf-form4_159779615491282.xml","form_type":"4"}},{"id":3054494,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-08-18T20:16:10.000Z","date":"2020-08-14","kind":"grant","acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units issued to the Reporting Person.  Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date.  One third of the shares underlying the restricted stock unit award vested on August 14, 2020.  One third of the shares will vest on August 14, 2021, and one third of the shares will vest on August 14, 2022, subject to the Reporting Person providing continuous service to the Issuer on such dates.  Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Of the shares of common stock reported, 18,756 Shares represent unvested restricted stock units."}],"balance_after":24173,"source":{"system":"sec-edgar","filing":"0001628280-20-012846","document":"wf-form4_159779615491282.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828020012846/wf-form4_159779615491282.xml","form_type":"4"}},{"id":3095403,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-01T16:10:58.000Z","date":"2020-06-30","kind":"tax_withholding","acquired":false,"shares":916,"price":9.32,"value":8537.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares withheld by X4 Pharmaceuticals Inc. to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units."}],"balance_after":7923,"source":{"system":"sec-edgar","filing":"0001628280-20-010103","document":"wf-form4_159363420470551.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828020010103/wf-form4_159363420470551.xml","form_type":"4"}},{"id":3095402,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-01T16:10:58.000Z","date":"2020-06-30","kind":"sale","acquired":false,"shares":1725,"price":9.04,"value":15594.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $8.54 to $9.19, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":8839,"source":{"system":"sec-edgar","filing":"0001628280-20-010103","document":"wf-form4_159363420470551.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000162828020010103/wf-form4_159363420470551.xml","form_type":"4"}},{"id":3484342,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (right to buy)","published_at":"2019-06-19T16:16:59.000Z","date":"2019-06-17","kind":"grant","acquired":true,"shares":15847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option shall vest on June 17, 2020, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option on the last day of each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":15847,"derivative":{"exercise_price":14.75,"expiration_date":"2029-06-17","underlying":"Common Stock","underlying_shares":15847},"source":{"system":"sec-edgar","filing":"0000899243-19-017421","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000089924319017421/doc4.xml","form_type":"4"}},{"id":3484341,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2019-06-19T16:16:59.000Z","date":"2019-06-17","kind":"grant","acquired":true,"shares":10564,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units to the Reporting Person under the Issuer's 2017 Equity Incentive Plan, with each restricted stock unit representing the contingent right to receive one share of common stock on the applicable vesting date. No amount was paid upon grant of the units. The restricted stock units vest in four equal annual installments on June 30, 2020, June 30, 2021, June 30, 2022 and June 30, 2023, subject to the Reporting Person continuing to provide services through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents unvested restricted stock units."}],"balance_after":10564,"source":{"system":"sec-edgar","filing":"0000899243-19-017421","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000089924319017421/doc4.xml","form_type":"4"}},{"id":3592905,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-15T16:39:21.000Z","date":"2019-03-13","kind":"grant","acquired":true,"shares":62633,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the Reporting Person's stock option to acquire 659,067 shares of X4 common stock for $0.99 per share that was assumed by the Issuer in the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) (\"X4\") on March 13, 2019 (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option shall vest on September 5, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. This amendment is being filed solely to correct the vesting schedule of the option included in the Form 4 filed on March 14, 2019."}],"balance_after":62633,"derivative":{"exercise_price":10.44,"expiration_date":"2028-10-03","underlying":"Common Stock","underlying_shares":62633},"source":{"system":"sec-edgar","filing":"0000899243-19-007975","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000089924319007975/doc4a.xml","form_type":"4/A","original_submission_date":"2019-03-14"}},{"id":3595622,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":83195,"kind":"person","name":"Mostafa Adam S.","position":1,"cik":"0001738081","reported_name":"Mostafa Adam S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-14T21:28:47.000Z","date":"2019-03-13","kind":"grant","acquired":true,"shares":62633,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the Reporting Person's stock option to acquire 659,067 shares of X4 common stock for $0.99 per share that was assumed by the Issuer in the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) (\"X4\") on March 13, 2019 (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vested on October 4, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":62633,"derivative":{"exercise_price":10.44,"expiration_date":"2028-10-03","underlying":"Common Stock","underlying_shares":62633},"source":{"system":"sec-edgar","filing":"0000899243-19-007821","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738081/000089924319007821/doc4.xml","form_type":"4"}}]}